Abbott India Limited vs Genpact Limited
Put two companies head-to-head — source-verified financials and AI-analysed SWOT, together in one view.
Abbott India Limited (Pharmaceuticals) and Genpact Limited (Professional services, business process outsourcing, and digital transformation) go head-to-head here — with source-verified financials and a full SWOT breakdown side by side on Nexvora Intelligence. On the figures reported, Genpact Limited leads on Revenue (approx.).
Genpact Limited leads on Revenue (approx.).
Choose Abbott India Limited if you are focused on the Indian pharmaceutical market and value strong multinational parentage, recognized chronic and specialty brands, and an established doctor–pharmacy distribution network with an emphasis on higher-margin branded formulations. Choose Genpact Limited if you are looking at global exposure in professional services, and prioritize deep process transformation expertise, broad cross-industry and geographic reach, and strong capabilities in finance operations, analytics, and automation. Given their different sectors and risk profiles, the right choice depends on whether your priorities lean toward India-centric branded pharmaceuticals or globally diversified business process and digital transformation services.
Grounded in the verified figures and SWOT shown — guidance, not investment advice.
Head-to-head highlights
| Metric | Abbott India Limited | Genpact Limited | Basis |
|---|---|---|---|
| Revenue (approx.) | INR 5,800-6,200 crore | Approximately $4.5 billion to $4.8 billion, unverified rough range | AI estimate |
An arrow marks the larger reported figure — a factual comparison, not a quality judgement. Verified figures come from official filings; AI estimates are approximate and unverified.
Abbott India Limited
Pharmaceuticals · India
Abbott India Limited is an Indian pharmaceutical company and a listed subsidiary of Abbott Laboratories. It markets branded prescription and over-the-counter healthcare products across therapeutic areas such as gastroenterology, women's health, metabolic disorders, central nervous system, pain management, and vaccines.
Verified financials
No source-verified financials available.
Strengths
- Strong parentage from Abbott Laboratories
- Recognized brands in chronic and specialty therapeutic areas
- Established doctor and pharmacy distribution network
- Focus on higher-margin branded formulations
Weaknesses
- High dependence on the Indian domestic pharmaceutical market
- Limited scale compared with India's largest pharma companies
- Exposure to price controls on essential medicines
- Relatively concentrated portfolio in select therapies
Opportunities
- Growth in chronic disease treatment demand in India
- Expansion in women's health, gastroenterology, and metabolic care
- Digital engagement with physicians and patients
- Leveraging Abbott's global portfolio for India-specific launches
Threats
- Intense competition from Indian generic and branded-generic companies
- Regulatory pricing pressure from India's drug price control regime
- Changes in physician prescribing behavior
- Supply chain and input cost volatility
Genpact Limited
Professional services, business process outsourcing, and digital transformation · United States
Genpact is a global professional services firm providing business process management, digital transformation, data analytics, and AI-enabled operations services. The company originated as a business unit supporting GE and now serves enterprises across industries such as financial services, healthcare, consumer goods, manufacturing, and high technology.
Verified financials
Strengths
- Deep process transformation expertise rooted in large-enterprise operations
- Broad global delivery footprint and cross-industry client base
- Strong capabilities in finance operations, analytics, and automation
- Established relationships with large enterprises
Weaknesses
- Exposure to pricing pressure in outsourcing and managed services
- Dependence on large enterprise transformation budgets
- Brand visibility is lower than some larger consulting and IT services competitors
- Need to continuously reskill workforce as AI changes service delivery
Opportunities
- Growing demand for generative AI-enabled enterprise operations
- Expansion in industry-specific digital transformation services
- Increased adoption of automation in finance, risk, and supply chain functions
- Potential to deepen partnerships with cloud and enterprise software platforms
Threats
- Competition from large consulting, IT services, and BPO firms
- Client insourcing or automation reducing traditional outsourcing demand
- Macroeconomic slowdowns delaying discretionary transformation projects
- Cybersecurity, data privacy, and regulatory compliance risks
Frequently asked
Answered from source-verified figures on this page.
Abbott India Limited vs Genpact Limited: which company leads overall?
Genpact Limited leads on Revenue (approx.).
Related market reports
Deep-dive intelligence on the markets these companies compete in.
India Digital Payments Market — Intelligence Report
Global Digital Payments & Real-Time Rails Market — Intelligence Report
Tokenized Real-World Assets and Digital Securities Market — Intelligence Report
Global Tokenized Real-World Assets, Digital Bonds and On-Chain Fund Administration Market — Intelligence Report
AI Analyst
Insights and answers generated live from Abbott India Limited vs Genpact Limited's verified data. Modeled estimates — not investment advice.
- Abbott India Limited is a listed Indian pharmaceutical subsidiary of Abbott Laboratories that markets branded prescription and over-the-counter healthcare products.
- Abbott India Limited operates across therapeutic areas including gastroenterology, women's health, metabolic disorders, central nervous system, pain management, and vaccines.
- Genpact Limited is a United States-based global professional services firm focused on business process outsourcing, digital transformation, data analytics, and AI-enabled operations.
- Notable: Genpact reported 2025 revenue of 5,079,879,000 USD and 2025 net income of 552,494,000 USD, compared with total assets of 4,987,153,000 USD in 2024.